Low dose indomethacin for symptomatic treatment of COVID-19

Ravichandran Rajan; Srinivasan Subramanian; Chritine Clark

doi:10.5455/IJMRCR.LOW-DOSE-INDOMETHACIN

E-ISSN 2534-9821

International Journal of Medical Reviews and Case Reports

2022, Vol: 6, Issue: 24

6/24Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

Copyright Transfer Form

« Previous Article

Letter to the Editor

Int J Med Rev Case Rep. 2020; 4(9): 69-70

doi: 10.5455/IJMRCR.LOW-DOSE-INDOMETHACIN

Low dose indomethacin for symptomatic treatment of COVID-19

Ravichandran Rajan, Srinivasan Subramanian, Chritine Clark.

Cited By: 3

Abstract
At present paracetamol is widely used for symptomatic treatment in Covid-19 with poor results. Indomethacin is a powerful anti inflammatory drug and gives relief in low doses also. We describe our experience in using indomethacin in a small number of patients with Covid-19 including those who would be classied as high risk. The response to indomethacin is rapid and would help reducing hospitalisation during the epidemic.

Key words: Indomethacin, Covid-19, Symptoms

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Ravichandran Rajan Articles by Srinivasan Subramanian Articles by Chritine Clark
	on Google
	on Google Scholar

This Article Cited By the following articles

Indomethacin: an exploratory study of antiviral mechanism and host-pathogen interaction in COVID-19 Expert Review of Anti-infective Therapy 2021; (): 1.	1

An open label randomized clinical trial of Indomethacin for mild and moderate hospitalised Covid-19 patients Sci Rep 2022; 12(1): .	2

Indomethacin: an exploratory study of antiviral mechanism and host-pathogen interaction in COVID-19 Expert Review of Anti-infective Therapy 2022; 20(3): 383.	3

How to Cite this Article

Pubmed Style

Rajan R, Subramanian S, Clark C. Low dose indomethacin for symptomatic treatment of COVID-19. Int J Med Rev Case Rep. 2020; 4(9): 69-70. doi:10.5455/IJMRCR.LOW-DOSE-INDOMETHACIN

Web Style

Rajan R, Subramanian S, Clark C. Low dose indomethacin for symptomatic treatment of COVID-19. https://www.mdpub.net/?mno=121224 [Access: February 24, 2023]. doi:10.5455/IJMRCR.LOW-DOSE-INDOMETHACIN

AMA (American Medical Association) Style

Rajan R, Subramanian S, Clark C. Low dose indomethacin for symptomatic treatment of COVID-19. Int J Med Rev Case Rep. 2020; 4(9): 69-70. doi:10.5455/IJMRCR.LOW-DOSE-INDOMETHACIN

Vancouver/ICMJE Style

Rajan R, Subramanian S, Clark C. Low dose indomethacin for symptomatic treatment of COVID-19. Int J Med Rev Case Rep. (2020), [cited February 24, 2023]; 4(9): 69-70. doi:10.5455/IJMRCR.LOW-DOSE-INDOMETHACIN

Harvard Style

Rajan, R., Subramanian, . S. & Clark, . C. (2020) Low dose indomethacin for symptomatic treatment of COVID-19. Int J Med Rev Case Rep, 4 (9), 69-70. doi:10.5455/IJMRCR.LOW-DOSE-INDOMETHACIN

Turabian Style

Rajan, Ravichandran, Srinivasan Subramanian, and Chritine Clark. 2020. Low dose indomethacin for symptomatic treatment of COVID-19. International Journal of Medical Reviews and Case Reports, 4 (9), 69-70. doi:10.5455/IJMRCR.LOW-DOSE-INDOMETHACIN

Chicago Style

Rajan, Ravichandran, Srinivasan Subramanian, and Chritine Clark. "Low dose indomethacin for symptomatic treatment of COVID-19." International Journal of Medical Reviews and Case Reports 4 (2020), 69-70. doi:10.5455/IJMRCR.LOW-DOSE-INDOMETHACIN

MLA (The Modern Language Association) Style

Rajan, Ravichandran, Srinivasan Subramanian, and Chritine Clark. "Low dose indomethacin for symptomatic treatment of COVID-19." International Journal of Medical Reviews and Case Reports 4.9 (2020), 69-70. Print. doi:10.5455/IJMRCR.LOW-DOSE-INDOMETHACIN

APA (American Psychological Association) Style

Rajan, R., Subramanian, . S. & Clark, . C. (2020) Low dose indomethacin for symptomatic treatment of COVID-19. International Journal of Medical Reviews and Case Reports, 4 (9), 69-70. doi:10.5455/IJMRCR.LOW-DOSE-INDOMETHACIN

Author Login Reviewer Login About Publisher Editorial Policies Peer Review Policy Editorial & Peer Review Process Author's Rights and Obligations Publication Ethics and Publication Malpractice Statement Conflict of Interest Policy Plagiarism Policy Protection of Research Participants (Statement On Human And Animal Rights)Privacy Policy Corrections, Retractions & Expressions of Concern Self-Archiving Policies Statement of Informed Consent Advertising Policy Terms of Use License Information Copyright Information



Copyright © 2023 International Journal of Medical Reviews and Case Reports All Rights Reserved. Subject to change without notice from or liability to International Journal of Medical Reviews and Case Reports. For best results, please use Internet Explorer or Google Chrome	Contact Information Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the International Journal of Medical Reviews and Case Reports editorial office as follows: Bulgarian Association of Young Surgeons (BAYS); National Center of Public Health and Analyses (NCPHA), floor 2, office № 31, Sofia 1431, Bulgaria. inkov@journalmedica.com Financial department is managed by International Sci Ink Press. It is a company registered in Bulgaria with registered no. 205414288 and registered address at 57 Antim I str., Vazrazhdane, Sofia, 1303, Bulgaria. Tel: +359883427500

Contact Information

How to cite this article